Recovery Modalities
Three biotech firms eye Nasdaq listings
Three biotech firms—including ADARx Pharma—are preparing Nasdaq listings, with ADARx targeting a $1.74 billion valuation for its hereditary angioedema therapy.
By Samoyed · Sep 22, 2026
Tag: differentia biotech
Endocrine Balance
Biotech and Digital Health Firms Expand Boards
Board appointments are reshaping biotech and digital health firms as August brings seasoned executives and scientific leaders onto boards to drive growth.
By Samoyed · Sep 21, 2026
Nutrient Synergy
Alumis lupus drug advances after trial setback
Alumis advances its lupus drug to Phase III trials despite mixed Phase IIb results, targeting a specific patient subgroup for better outcomes.
By Samoyed · Sep 3, 2026
Endocrine Balance
Novartis Announces Positive Phase III Results for Remibrutinib
Novartis announces positive Phase III results for Remibrutinib, a new oral treatment for relapsing multiple sclerosis showing significant efficacy over teriflun
By Samoyed · Sep 1, 2026
Recovery Modalities
HiRO and Differentia Biotech collaborate on trial simulation
HiRO and Differentia Biotech collaborate on advanced clinical trial simulation models. Learn how this AI-driven partnership aims to support biopharmaceutical sp
By emily johnson · Aug 31, 2026